Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Merkel Cell 2

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × ALT-803 × Dermatologic × Clear all
NCT03853317 2024-08-09

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

ImmunityBio, Inc.

Phase 2 Terminated
9 enrolled 13 charts
Dermatologic

Carcinoma, Merkel Cell

NCT02465957 2024-05-02

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

ImmunityBio, Inc.

Phase 2 Terminated
7 enrolled 11 charts
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡